Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Aliskiren hemifumarate].

K Kappert1, T Unger, U Kintscher

  • 1Center vor Cardiovascular Research, CCR, Institut für Pharmakologie, Charité-Universitätsmedizin Berlin, Detschland.

Deutsche Medizinische Wochenschrift (1946)
|May 10, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating immune cells in cerebral small vessel disease: a systematic review.

Biogerontology·2025
Same author

Upper limb movement quality measures: comparing IMUs and optical motion capture in stroke patients performing a drinking task.

Frontiers in digital health·2024
Same author

The role of receptor MAS in microglia-driven retinal vascular development.

Angiogenesis·2019
Same author

Excited state dynamics and conformations of a Cu(ii)-phthalocyanine-perylenebisimide dyad.

Physical chemistry chemical physics : PCCP·2017
Same author

[Management of different cardiovascular risk factors with a combination tablet (polypill)].

Herz·2017
Same author

[Molecular Pathological Aspects in Visceral Surgery].

Zentralblatt fur Chirurgie·2016
Same journal

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Emergency management of sickle cell disease].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Diagnosis of Congenital Hemolytic Anemias in Adults].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[46-year-old female patient with right upper abdominal pain].

Deutsche medizinische Wochenschrift (1946)·2026
See all related articles

Aliskiren, a novel renin inhibitor, effectively reduces blood pressure in hypertensive patients. Ongoing research explores its potential benefits for heart failure and diabetic nephropathy beyond blood pressure control.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Aliskiren is the first-in-class direct renin inhibitor targeting the renin-angiotensin system.
  • Approved for hypertension treatment in the US (2007) and Europe (2007).
  • Demonstrated effective blood pressure reduction in clinical trials.

Purpose of the Study:

  • To evaluate the efficacy of aliskiren in hypertension.
  • To investigate potential benefits of aliskiren in heart failure and diabetic nephropathy.
  • To assess long-term morbidity and mortality benefits of aliskiren.

Main Methods:

  • Clinical trials evaluating blood pressure reduction.
  • Ongoing trials assessing effects on heart failure markers (NTproBNP).
  • Ongoing trials assessing effects on diabetic nephropathy markers (urinary albumin/creatinine ratio).

Related Experiment Videos

Main Results:

  • Aliskiren effectively reduces blood pressure in hypertensive patients.
  • Preliminary data suggests beneficial effects in heart failure and diabetic nephropathy.
  • Reduction in urinary albumin/creatinine ratio and NTproBNP observed in specific trials.

Conclusions:

  • Aliskiren is an effective antihypertensive agent.
  • Further long-term clinical trials are needed to determine morbidity and mortality benefits.
  • Aliskiren shows promise for treating additional conditions like heart failure and diabetic nephropathy.